Significant Changes Expected in Generic Drug Pricing

Recent tariff announcements from President Donald Trump may lead to big shifts in the pricing of generic drugs.

In a post on Truth Social, Trump indicated that generic drug imports would initially enjoy a zero tariff for two years, followed by two major tariff increases thereafter.

The president explained, “The purpose of this policy is to protect the American people.” He added that these tariffs aim to encourage pharmaceutical companies to relocate their manufacturing to the U.S.

According to Trump, “Starting August 1, 2026, all generic drugs entering the United States will have a zero percent tariff for two years, after which it will rise to 100% for one year, then to 200%.”

The Food and Drug Administration reports that generic drugs comprise 90% of prescriptions dispensed in the U.S., with half of these drugs being manufactured in India. Notably, a significant portion—95% of imported ibuprofen and 70% of imported acetaminophen—comes from China.

White House Press Secretary Khush Desai referred to other administration efforts aimed at bringing manufacturing back to the nation. In an email, she asserted that the President has been successful in securing substantial reshoring programs from global pharmaceutical companies through initiatives like the Most Favored Nation Agreement and the Section 232 Tariff Program.

Experts conveyed to CBS News that it’s likely manufacturers will pass along the costs of these tariffs to consumers. However, they opined that the resultant price hikes might be relatively modest due to already low pricing.

At the same time, some manufacturers might opt to exit the U.S. market altogether, raising concerns about potential drug shortages. Trump remarked, “Across the United States, pharmaceutical facilities are being built at levels never seen before. Thank you for your interest in this issue!”